Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas - Results of a prospective randomized study of the German Low Grade Lymphoma Study Group;Rituximab zur remissionsinduktion bei rezidivierten und refraktären indolenten lymphomen und mantelzell-lymphomen: Ergebnisse einer prospektiv randomisierten studie der Deutschen Studiengruppe für Niedrig Maligne Lymphome (GLSG)

Deutsche Medizinische Wochenschrift

Volumn 127, Issue 43, 2002, Pages 2253-2258

  Forstpointner, Roswitha ^a   Hanel A ^b   Repp, R ^c   Hermann, S ^d   Metzner, B ^e   Pott, C ^f   Hartmann, F ^g   Rothmann, F ^h   Bock H P ⁱ   Wandt, H ^j   Unterhalt, M ^a   Hiddemann, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d Section of Pathology   (Germany)

^e KLINIKUM OLDENBURG   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g SAARLAND UNIVERSITY   (Germany)

^h KLINIKUM ERNST VON BERGMANN   (Germany)

ⁱ Hämatologisch Onkologische Praxis   (Germany)

^j KLINIKUM NÜRNBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DIMETINDENE; FLUDARABINE; MITOXANTRONE; PARACETAMOL; RITUXIMAB;

ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HUMAN; INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 18644384409     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35017     Document Type: Article

References (46)

1. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 1984; 63: 1424-1433
2. Borisch B, Semac I, Soltermann A, Palomba C, Hoessli DC. Anti-CD20 treatments and the lymphocyte membrane: Pathology for therapy. Verh Dtsch Ges Pathol 2001; 85: 161166
3. Bosch F, Perales M, Cobo F et al. Fludarabine, cyclophosphamid and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia or follicular lymphoma (abstr). Blood 1997; 90: 2360
4. Cartwright R, Brincker H, Carli PM et al. The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer 1999; 35: 627-633
5. Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 2002; 87: 33-43
6. Coiffier B, Lepage MD, Briere J et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med 2002; 346: 235-242
7. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 2001; 97: 101-106
8. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999; 26: 88-96(Suppl 14
9. Czuczman MS. Combination chemotherapy and rituximab. Anticancer Drugs 2001; 12: S15-19(Suppl 2
10. De Vita V, Jaffe E, Mauch P. Lymphocytic lymphomas. Philadelphia, PA: Lippincott-Raven, In De Vita VT, Hellman S, RosenbergSA (eds): Cancer: Principles and Practice of Oncology. 1989: 1741-1808
11. Emmanouilides C, Rosen P, Telatar M et al. Excellent tolerance of rituximab when given after mitoxantrone/cyclophosphamide: An effective and safe combination for indolent non-Hodgkin's lymphoma. Clin Lymphoma 2000; 1: 146-151; discussion 52-3.
12. Falkson CI. Fludarabine: A phase II trial in patients with previously treated low-grade lymphoma. Am J Clin Oncol 1996; 19: 268-270
13. Feuring-Buske M, Kneba M, Unterhalt M et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000; 79: 493-500
14. Foran JM, Cunningham D, Coiffier B et al. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response. Ann Oncol 2000; 11: 117-121(Suppl 1
15. Foran JM, Rohatiner AZ, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324
16. Ghielmini M, Schmitz SF, Burki K et al. Swiss Group for Clinical Cancer Research (SAKK). The effect of Rituximab on patients with follicular and mantlecell lymphoma. Ann Oncol 2000; 11: 123-126(Suppl 1
17. Hainsworth JD. Rituximab as first-line systemic therapy for patients with low-grade lymphoma. Semin Oncol 2000; 27: 25-29(Suppl 12
18. Hainsworth JD, 3rd Burris HA, Morrissey LH et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052-3056
19. Hiddemann W. Unterhalt M, Herrmann R et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998; 16: 1922-1930
20. Hiddemann W, Unterhalt M, Pott C et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin Oncol 1993; 20: 28-31 (Suppl 7
21. Hiddemann W, Unterhalt M, Wandt H et al. Myeloablative radiochemotherapy followed by blood-stemcell-transplantation significantly prolongs the disease-free intervall in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha: Results of a prospective randomized comparison by the German Low Grade Lymphoma Study Group (GLSG) (abstr). Blood 1999; 94: 2715
22. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471-1475(23
23. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294
24. Johnston JB, Verburg L, Shore T, Williams M, Israels LG, Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia 1994; S140-143(Suppl 1
25. Klasa R, Meyer R, Shustik C et al. Fludarabine versus CVP in previously treated patients with progressive low grade non-Hodgkin's lymphoma (Ig-NHL) (abstr). Proc Am Soc Clin Oncol 1999; 18: 28
26. Lazzarino M, Orlandi E, Montillo M et al. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 59-64
27. Lossos IS, Paltiel O, Polliack A. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas. Leuk Lymphoma 1999; 33:155-160
28. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: Results of a phase 1 multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274
29. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195
30. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833
31. McLaughlin P, Hagemeister FB, Rodriguez MA et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000; 27: 37-41(Suppl 12
32. McLaughlin P, Hagemeister FB, Romaguera JE et al. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262-1268
33. McLaughlin P, Hagemeister FB, Jr. Swan F et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994; 12: 575-579
34. Micallef IN, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947-955
35. Park S, Brice P, Noguerra ME et al. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2000; 26: 321-326
36. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856-862
37. Reed JC, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol 2002; 29: 10-24(Suppl 2
38. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445
39. Rohatiner A, Gregory W, Peterson B et al. A meta-analysis of randomised trials evaluating the role of interferon (IFN) as treatment for follicular lymphoma (FL) (abstr). Proc Am Soc Clin Oncol 1998; 17: 4a
40. Santini G, Contu A, Porcellini A et al. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG). Haematologica 1991; 76: 485-490
41. Santini G, Nati S, Spriano M et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 282-286
42. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 673-683
43. Silver RT, Jr. Case DC, Wheeler RH et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 1991; 9: 754-761
44. Tobinai K, Kobayashi Y, Narabayashi M et al. The IDEC-C2B8 Study Group. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol 1998; 9: 527-534
45. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-397
46. Zinzani PL, Tosi P, Visani G et al. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994; 47: 301-306